136 related articles for article (PubMed ID: 11279659)
1. Excessive anticoagulation in patients with mild renal insufficiency receiving long-term therapeutic enoxaparin.
Busby LT; Weyman A; Rodgers GM
Am J Hematol; 2001 May; 67(1):54-6. PubMed ID: 11279659
[TBL] [Abstract][Full Text] [Related]
2. Bridging of oral anticoagulation with low-molecular-weight heparin: experience in 373 patients with renal insufficiency undergoing invasive procedures.
Hammerstingl C; Omran H;
Thromb Haemost; 2009 Jun; 101(6):1085-90. PubMed ID: 19492151
[TBL] [Abstract][Full Text] [Related]
3. Low-molecular-weight heparins in renal impairment and obesity: available evidence and clinical practice recommendations across medical and surgical settings.
Nutescu EA; Spinler SA; Wittkowsky A; Dager WE
Ann Pharmacother; 2009 Jun; 43(6):1064-83. PubMed ID: 19458109
[TBL] [Abstract][Full Text] [Related]
4. Low molecular weight heparin and bleeding in patients with chronic renal failure.
Crowther M; Lim W
Curr Opin Pulm Med; 2007 Sep; 13(5):409-13. PubMed ID: 17940486
[TBL] [Abstract][Full Text] [Related]
5. Low molecular weight heparin in the treatment of venous and arterial thromboses in the premature infant.
Michaels LA; Gurian M; Hegyi T; Drachtman RA
Pediatrics; 2004 Sep; 114(3):703-7. PubMed ID: 15342842
[TBL] [Abstract][Full Text] [Related]
6. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
7. Low molecular weight heparins in renal failure.
Von Visger J; Magee C
J Nephrol; 2003; 16(6):914-6. PubMed ID: 14736021
[TBL] [Abstract][Full Text] [Related]
8. Use of low-molecular-weight heparin to bridge therapy in obese patients and in patients with renal dysfunction.
George-Phillips KL; Bungard TJ
Pharmacotherapy; 2006 Oct; 26(10):1479-90. PubMed ID: 16999658
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of enoxaparin compared with unfractionated heparin and oral anticoagulants for prevention of thromboembolic complications in cardioversion of nonvalvular atrial fibrillation: the Anticoagulation in Cardioversion using Enoxaparin (ACE) trial.
Stellbrink C; Nixdorff U; Hofmann T; Lehmacher W; Daniel WG; Hanrath P; Geller C; Mügge A; Sehnert W; Schmidt-Lucke C; Schmidt-Lucke JA;
Circulation; 2004 Mar; 109(8):997-1003. PubMed ID: 14967716
[TBL] [Abstract][Full Text] [Related]
10. Safety of low-dose subcutaneous enoxaparin for the prevention of venous thromboembolism after primary intracerebral haemorrhage.
Tetri S; Hakala J; Juvela S; Saloheimo P; Pyhtinen J; Rusanen H; Savolainen ER; Hillbom M
Thromb Res; 2008; 123(2):206-12. PubMed ID: 18420258
[TBL] [Abstract][Full Text] [Related]
11. Administration of enoxaparin by continuous infusion in a naturalistic setting: analysis of renal function and safety.
Kane-Gill SL; Feng Y; Bobek MB; Bies RR; Pruchnicki MC; Dasta JF
J Clin Pharm Ther; 2005 Jun; 30(3):207-13. PubMed ID: 15896237
[TBL] [Abstract][Full Text] [Related]
12. How useful is determination of anti-factor Xa activity to guide bridging therapy with enoxaparin? A pilot study.
Hammerstingl C; Omran H; Tripp C; Poetzsch B
Thromb Haemost; 2009 Feb; 101(2):325-32. PubMed ID: 19190817
[TBL] [Abstract][Full Text] [Related]
13. Low molecular weight heparins in patients with renal insufficiency.
Symes J
CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
[TBL] [Abstract][Full Text] [Related]
14. [Perioperative Bridging with Enoxaparin. Results of the Prospective BRAVE Registry with 779 Patients].
Omran H; Hammerstingl C; Paar WD;
Med Klin (Munich); 2007 Oct; 102(10):809-15. PubMed ID: 17928964
[TBL] [Abstract][Full Text] [Related]
15. Prophylactic anticoagulation with enoxaparin: Is the subcutaneous route appropriate in the critically ill?
Priglinger U; Delle Karth G; Geppert A; Joukhadar C; Graf S; Berger R; Hülsmann M; Spitzauer S; Pabinger I; Heinz G
Crit Care Med; 2003 May; 31(5):1405-9. PubMed ID: 12771610
[TBL] [Abstract][Full Text] [Related]
16. Low-molecular-weight heparin use in the obese, elderly, and in renal insufficiency.
Clark NP
Thromb Res; 2008; 123 Suppl 1():S58-61. PubMed ID: 18809206
[TBL] [Abstract][Full Text] [Related]
17. Renal failure and low molecular weight heparins. A dangerous liaison? The case of retroperitoneal hematoma.
Kravitz MS; Mishaal RA; Shoenfeld Y
Isr Med Assoc J; 2005 Sep; 7(9):600-1. PubMed ID: 16190487
[No Abstract] [Full Text] [Related]
18. Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency.
Lim W; Dentali F; Eikelboom JW; Crowther MA
Ann Intern Med; 2006 May; 144(9):673-84. PubMed ID: 16670137
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight heparin (LMWH) in the treatment of thrombosis.
Holzheimer RG
Eur J Med Res; 2004 Apr; 9(4):225-39. PubMed ID: 15210403
[TBL] [Abstract][Full Text] [Related]
20. Retrospective evaluation of a pharmacokinetic program for adjusting enoxaparin in renal impairment.
Kruse MW; Lee JJ
Am Heart J; 2004 Oct; 148(4):582-9. PubMed ID: 15459586
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
